PARP inhibitor cuts cancer progression by nearly half in BRCA-positive prostate cancer

Credit: Getty Images/Mark Kostich

By Olivia Bowthorpe

Adding the PARP inhibitor niraparib to standard hormone treatment may significantly delay progression of advanced prostate cancer with homologous recombination repair (HRR) gene alterations.

In the AMPLITUDE phase III study, 696 men with HRR-positive metastatic castration-sensitive prostate cancer (mCSPC) received either niraparib or placebo, together with the standard of care, abiraterone acetate and prednisone (AAP). Treatment was delivered in the first six months of androgen deprivation therapy.1